INTERCEPT PHARMACEUTICALS, INC. Quarterly Interest Expense in USD from Q3 2011 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of the cost of borrowed funds accounted for as interest expense.
Summary
Intercept Pharmaceuticals, Inc. quarterly/annual Interest Expense history and growth rate from Q3 2011 to Q3 2023.
  • Intercept Pharmaceuticals, Inc. Interest Expense for the quarter ending September 30, 2023 was $1.8M, a 65.6% decline year-over-year.
  • Intercept Pharmaceuticals, Inc. Interest Expense for the twelve months ending September 30, 2023 was $11.7M, a 64.1% decline year-over-year.
  • Intercept Pharmaceuticals, Inc. annual Interest Expense for 2022 was $21.4M, a 60.7% decline from 2021.
  • Intercept Pharmaceuticals, Inc. annual Interest Expense for 2021 was $54.4M, a 13.2% increase from 2020.
  • Intercept Pharmaceuticals, Inc. annual Interest Expense for 2020 was $48.1M, a 16.8% increase from 2019.
Interest Expense, Trailing 12 Months (USD)
Interest Expense, Quarterly (USD)
Interest Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 $11.7M $1.8M -$3.44M -65.6% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-06
Q2 2023 $15.1M $2.81M -$2.43M -46.3% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-02
Q1 2023 $17.5M $2.81M -$3.86M -57.9% Jan 1, 2023 Mar 31, 2023 10-Q 2023-04-27
Q4 2022 $21.4M $4.24M -$11.1M -72.3% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-02
Q3 2022 $32.5M $5.24M -$8.86M -62.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 $41.3M $5.24M -$7.35M -58.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-06
Q1 2022 $48.7M $6.67M -$5.75M -46.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-04-27
Q4 2021 $54.4M $15.3M +$3.06M +25% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-02
Q3 2021 $51.4M $14.1M +$2M +16.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-01
Q2 2021 $49.4M $12.6M +$656K +5.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 $48.7M $12.4M +$642K +5.45% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q4 2020 $48.1M $12.3M +$627K +5.39% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-02
Q3 2020 $47.4M $12.1M +$296K +2.51% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $47.1M $11.9M +$2.05M +20.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
Q1 2020 $45.1M $11.8M +$3.94M +50.2% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $41.1M $11.6M +$3.87M +49.9% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-02
Q3 2019 $37.3M $11.8M +$4.12M +53.8% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $33.1M $9.88M +$2.3M +30.2% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $30.9M $7.84M +$330K +4.4% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 $30.5M $7.75M +$323K +4.35% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-25
Q3 2018 $30.2M $7.67M +$317K +4.31% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 $29.9M $7.59M +$310K +4.26% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 $29.6M $7.51M +$302K +4.19% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q4 2017 $29.3M $7.43M Oct 1, 2017 Dec 31, 2017 10-K 2020-02-25
Q3 2017 $7.35M +$289K +4.09% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-01
Q2 2017 $7.28M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 $7.21M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
Q3 2016 $7.07M Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-06
Q3 2012 -$3.41K* -$6.3K -218% Jul 1, 2012 Sep 30, 2012 10-Q/A 2012-12-21
Q3 2011 $2.89K* Jul 1, 2011 Sep 30, 2011 10-Q/A 2012-12-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.